



# CURRENT FMD LABORATORY ACTIVITIES IN [MYANMAR]

**SEACFMD Labnet Meeting**  
**Pakchong, Thailand**  
**November 4-5, 2019**



# OUTLINE

- FMD situation
- FMD laboratory diagnosis, including virus serotyping and genotyping report
- FMD research activities and achievements
- Post vaccination monitoring activities and results
- Quality assurance
- Constraints and possible solution
- Future Plans


# FMD Situation

Myanmar is FMD endemic country.

- **Serotype O (Mya98):** Predominant Strain
  - **O/Ind-2001d:** in 2015 in Maung Taw township, Rakhine State and widely spread in 2017
- **Serotype A/SEA-97**
  - in 1999 in Tanintharyi Region
  - in 2010 in Rakhine State
  - in 2015 in Mandalay Region
- **Serotype Asia1**
  - in 2005 in Kayah State and Magway Region
  - in 2017 in Rakhine State


# FMD SITUATION (2018)

Month	States/ Regions	Townships	Affected Villages	Myanmar Lab -Result
May 18	Rakhine	Kyauktaw	21	Type "O"
		Ramree	8	Type "O"
Sept 18	Mandalay	Pyin Oo Lwin	1	Untyped
Oct 18	Bago	Nyaunglebin	4	Type "O"
	Shan	Muse	2	Untyped
	Mandalay	Thazi	1	Type "O"
		NyaungU	1	Type "O"
		Yamethin	1	Type "O"
Magway	Chauk	2	Type "O"	
Nov 18	Bago	Kawa	1	Type "O"
	Sagaing	YeU	1	Untyped
		Yinmarbin	4	Type "O"
	<b>6</b>	<b>12</b>	<b>47</b>	



# FMD SITUATION (2019)

Month	States/ Regions	Townships	Affected Villages	Myanmar Lab –Result
Jan 2019	Magway	Taungdwingyi	1	Type "O"
July 2019	Sagaing	Kanbalu	1	Type "O"
July 2019	Kachin	Myitkyina	1	Type "O"
Sept 2019	Magway	Salin	1	Type "O"
Oct 2019	Sagaing	Wuntho	1	Type "O"
Oct 2019	Sagaing	Khin-U	2	Type "O"
Oct 2019	Sagaing	Ye-U	4	Type "O"
Oct 2019	Magway	Magway	1	Type "O"
	<b>Total</b>	<b>8</b>	<b>12</b>	



## FMD Virus characterization (serotyping and genotyping)

Year	No. samples submitted to national lab	No. of serotype O viruses	No. of serotype A viruses	No. of serotype Asia 1	No virus detected
2017	43	36	-	4	3
2018	44	20	-	-	24
2019	38	26	-	-	12

- No virus detected samples – poor quality of sample

# FMD Virus characterization (serotyping and genotyping)

Year	No. of samples submitted to RRL/WRL	O/Mya-98	O/PanAsia	O/Cathay	O/Ind2001d *O/Ind2001e	A/SEA-97	Asia 1
2017	32	3	-	-	11	-	1
2018	20 (Japan/ APQA)	4			*6		
2019	15	1	-	-	*1	-	-



**THE Pirbright INSTITUTE**

**FMD Genotyping Report**

Lab Reference WRL batch Number: WRL/FMD/2019/00024

Sender Details: Dr. Boloruya Purevuren, Yangon FMD Laboratory, Research and Disease Control Division, Livestock Breeding and Veterinary Department, No. 36, Ministry of Agriculture, Livestock and Irrigation, Nay Pyi Taw, Republic of Myanmar, EMAIL: b.purevuren@biac.mt, PHCNE: 95-9-799463695

Date Received: 23/05/2019  
Country of Origin\*: MYANMAR

Signposting work has now been completed in respect of the samples you submitted and the details are as attached. Please note that all of our phylogenetic trees can be accessed via the internet at: <http://www.wrlfmd.org/>

Results Approved By:  Official Stamp: 


Date: 2/7/2019

c.c.: I. Bakali-Kasimi, A Bin-Tarif, D King, M Henstock, N Knowles, A Lud, N Lyons, N Maprice, S Metwally, V Mouton, S Parida, J Pinto, E Rajzman, B Statham, K Sumption, J Wadsworth, B Wood, FAD Circulation, OIE Animal Health Information, Regional OIE Delegate.

To help us improve the quality of our service, please send any suggestions or requests to the Reference Laboratory by email ([refabsfeedback@pirbright.ac.uk](mailto:refabsfeedback@pirbright.ac.uk)).

Page 3 of 8 \* Data supplied by the customer Ref: WRL/2019/00024

Report on FMDV O in Myanmar in 2013, 2018  
Batch: WRL/FMD/2019/00024





# Outbreak Investigation (2018)

## FMD Outbreak Investigations in 2018

1. Pyin Oo Lwin Township
2. Nyaung U Township
3. Yamethin Township
4. YeU Township


❖ FMD outbreaks occurred in 12 townships, Affecting 2959 animals in Bago, Magway, Mandalay, Rakhine, Sagaing and Shan Regions



# Outbreak Investigation (2019)

- 1.Kantnalu
- 2.Khin U
- 3.Wet let
- 4.Ye U Township
- 5.Salin Township

❖ FMD outbreaks occurred in 8 township in Magway, Sagaing Regions and Kachin State.



# PVM activities and findings


## OIE-LBVD FMD Myanmar Control Project :

Between May 2017-2018, 4 round vaccination campaign was completed in the 24 townships

1<sup>st</sup> PVM was conducted in 2017 (Type O and A)

2<sup>nd</sup> PVM was conducted in August 2018 (Type O, A and Asia-1)

Myanmar Vaccination Campaign




# PVM activities and findings

## Purpose of Study:

- ❖ To monitor the occurrence of FMD and evidence of circulating field virus in target and non-target villages
- ❖ To measure the level of herd immunity achieved through annual vaccination in the targeted villages
- ❖ To evaluate vaccination coverage of village and township level in target areas
- ❖ To confirm the vaccines are effective

## Study Area:

- ❖ 4 townships in Sagaing region
- ❖ 6 townships in Mandalay region



# PVM activities and findings

## Methodology

### 1. Random Sampling

**10 townships were selected among 24 townships**

**3 villages (vaccinated) and 3 villages (non-vaccinated)/township**

**15 blood samples/village**

- 10 townships x 6 villages x 15 blood samples = 900
- Sampling across 3 age categories:
  - 1-18 months (~ 1 yr of exposure)
  - 19-36 months (~ 2 yrs of exposure)
  - > 36 months



# PVM activities and findings

## Methodology

### 2. Laboratory Testing

- ❖ Total of 900 samples (vaccinated & non-vaccinated) were tested by NSP ELISA (The interpretation of results: PI value  $\geq 50\%$  - positive)
- ❖ 450 samples (vaccinated) were tested by LPB ELISA (Type O, A and Asia1) (The interpretation of results: Log10 titre  $\geq 1.9$  – positive)

### 3. Data Analysis


- ❖ Calculation of Vaccination Coverage (Expected:  $>90\%$ )
- ❖ Measure the NSP antibody level by age categories
- ❖ Measure the Protective Immunity of Serotype O, A and Asia-1 of Village/Township Level at 95% Confidence Interval

## Summary of PVM 2018 outcomes

Indicator	Target	Myanmar	
		Vaccinated	Non-Vaccinated
Number of villages sampled	30	30	30
Number of animals sampled	450	450	450
Age 1-18 months	150	113	104
Age 19-36 months	150	168	178
Age >36 months	150	169	168
Vaccination coverage (% animals) 2018	>90%	<b>96%</b>	-
NSP prevalence		<b><u>25%</u></b>	<b><u>22%</u></b>
Age 1-18 months	<10%	13%	14%
Age 19-36 months	<20%	23%	16%
Age >36 months	<40%	35%	34%

# Measure of NSP Antibody Level in Vaccinated Villages (High Risk), Non-Vaccinated Villages (Low Risk) and BaseLine Survey


- 25% (112/450) Sera positive in Vaccinated villages (High risk)
- 22% (100/450) Sera positive in Non-vaccinated villages (Low risk)
- 29% (1162/4075) sera positive in Baseline survey



## Summary of PVM 2018 outcomes (Con;)


Indicator	Myanmar		
	Serotype <b>O</b>	Serotype <b>A</b>	Serotype <b>Asia1</b>
Protective prevalence LPB ELISA	<b><u>67%</u></b>	<b><u>71%</u></b>	<b><u>81%</u></b>
One time-vaccinated/NSP-negative	30%	40%	53%
One time-vaccinated/NSP-positive	67%	67%	<b>100%</b>
Two time-vaccinated/NSP-negative	65%	70%	81%
Two time-vaccinated/NSP-positive	87%	87%	93%

# Protective Immunity Level of Serotype O, A and Asia-1



# Comparison of Protective Immunity Level in One time and Two time vaccination


Protective Immunity of One Time and Two Time Vaccination




## Summary of PVM 2018 outcomes (Con;)

Indicator	Myanmar		
	Serotype <b>O</b>	Serotype <b>A</b>	Serotype <b>Asia1</b>
non-vaccinated/NSP-negative	38%	50%	50%
non-vaccinated/NSP-positive	50%	50%	50%
*vaccinated/NSP-negative	62%	67%	78%
*vaccinated/NSP-positive	86%	86%	93%
<b>* Vaccinated at least once</b>			

# Township level Protective Immunity of Serotype O,A and Asia-1 (95% C.I)



# Village level Protective Immunity of Serotype O,A and Asia-1 (95% C.I)



# Conclusion

- ❖ **Vaccination Coverage was 96% (Target:> 90%)**
- ❖ **NSP Prevalence in Vaccinated villages (High risk) is slightly higher than the Non-vaccinated villages (Low risk)**
- ❖ **Endemic level after vaccination (13% Vac, 14% non-vac) less than before vaccination (observed in <18 M calves)**
- ❖ **Vaccine derived antibody was higher than natural exposure (O:38% vs62% , A: 50 vs 67%, Asia1: 50% vs 78%)**
- ❖ **Protective immunity of O, A and Asia1 in two time vaccination is significantly higher than the one time vaccination**
- ❖ **Target herd immunity for both O, A and Asia-1 was achieved by almost 80% of vaccinated villages**

# Quality assurance

- ❖ Development of SOP ( V2) for RT-PCR, Antigen, NSP , Virus Isolation and LP ELISA by Experts from Animal and Plant Quarantine Agency from South Korea.
- ❖ Internal Quality Control (IQC) ( Supervised by MPI)
  - QC chart for ELISA (Control )
  - Excel sheets for progressive monitoring and calculating for all tests
- ❖ External Quality Control (EQC)
  - Equipment maintenance and Calibration
- ❖ Participation in proficiency testing conducted by RRL (2013,2015,2017)

SOP	Version- 2.0
Publication Date	05.07.2019



## National FMD Laboratory

### Standard Operating Procedure

#### Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for detection of FMDV



Dr. Joo Won, Veterinary Researcher, APQ, A, Korea  
Dr. Min Sun, Research Officer, FMD Laboratory, Yangon  
Dr. Yoon Young, Researcher, BSL-2 FMD Laboratory, Nay Pyi Taw  
Dr. Mon Oo, Researcher, BSL-2 FMD Laboratory, Nay Pyi Taw  
Dr. Lisa Sand Lynn, Researcher, BSL-2 FMD Laboratory, Nay Pyi Taw

# Constrains and solutions

<b>Constrains in FMD Lab/Research activities</b>	<b>Possible solutions</b>
Reagents and chemicals	<ul style="list-style-type: none"><li>• Request to government to support more budget</li><li>• Request to Developing partners</li></ul>
Sample submission	<ul style="list-style-type: none"><li>• Meeting with local veterinarian to collect more FMD outbreak samples and submit to National FMD Lab</li></ul>
Poor Quality of FMD Sample	<ul style="list-style-type: none"><li>• Improve staff skill</li><li>• Apply molecular methods</li></ul>
Reporting and Sharing information	<ul style="list-style-type: none"><li>• Strengthen official reporting system and surveillance</li></ul>

## Future research plans

### **JICA-LBVD Project : The Project for Improvement of Foot and Mouth Disease Control (2019-2024)**

#### **Project Purpose :**

**Control system for FMD epidemics is strengthened in National FMD Laboratory in Yangon and in the pilot sites in Project areas**


#### **Project sites:**

**Yangon FMD Laboratory, Naypyitaw BSL2 FMD diagnostic Laboratory, Regional Veterinary Diagnostic Laboratory**

**Output 1 : Mass Production of FMD Vaccine**

**Output 2: Rapid diagnosis & Epidemiological survey**

**Output 3: Strengthened Vet Services in the pilot sites & Networking among the institutions**



## Future research plans

### **FMD Active Surveillance and Questionnaire activities**

**Objectives:** To understand FMD prevalence, distribution, risk and economic impact at target townships

**Study Area :** Magway

Naypyitaw

Sagaing

Rakhine

Tanintharyi

Kayin

## Future research plans

- ❖ **OIE-LBVD Myanmar FMD Control Project (2016-2020)**
  - PVM study testing by LPB ELISA
  - 7th round Vaccination Campaign
  - Farmer/Trader FMD Awareness Training
  
- ❖ **Revising the National Strategy Framework on Foot and Mouth Control Myanmar with OIE and LBVD**
  
- ❖ **Cooperate with KOICA for technical exchange (SURVEILLANCE AND DIAGNOSIS DEVELOPMENT OF FOOT AND MOUTH DISEASE IN MYANMAR)**
  
- ❖ **Increase follow up outbreak investigation to understand virus circulation**

# Thank you for your Attention!

